Aortic Diseases, Coronary Artery Disease, Coronary Heart Disease, Valve Heart Disease
Conditions
Brief summary
Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes. This muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built. This database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.
Detailed description
1\. Establish a cohort of perioperative surgical patients across multiple medical centers, tracking them from enrollment through 1 year post-surgery, and build a database of data relevant to patient outcomes; 2. Investigate the impact of preoperative psychological and physical factors on short-term postoperative complications in surgical patients, develop predictive models, and conduct prospective validation; 3. Investigate the impact of preoperative psychological, physical, and social factors on long-term postoperative complications; 4. Investigate the incidence of acute and chronic postoperative pain, associated risk factors, and their impact on prognosis; 5. Investigate the optimal perioperative transfusion strategies for allogeneic blood products based on causal relationships, develop predictive models, and validate them.
Interventions
PROCEDURECardiac surgey
Cardiac surgey
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031
Exclusion criteria
* Refusal to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of major adverse cardiac and cerebrovascular events (MACCE) | 4, 12 weeks and 1years after surgery | Myocardial infarction; New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion; Death |
| Incidence of Perioperative Transfusion of Allogeneic Blood Products | 30 days after surgery | Allogeneic red blood cells, plasma, platelets, and blood coagulation factors |
| Amount of Allogeneic Blood Products Transfused During the Perioperative Period | 30 days after surgery | Allogeneic red blood cells, plasma, platelets, and blood coagulation factors |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of perioperative myocardial infarction | 4, 12 weeks and 1years after surgery | Myocardial infarction |
| Incidence of New-onset stroke | 4, 12 weeks and 1years after surgery | New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion |
| Incidence of death | 4, 12 weeks and 1years after surgery | death |
| Incidence of acute kidney injury | 7days after suegery | acute kidney injury was defined by guidelines of kindey disease：improving global outcomes（KIDGO） |
| Incidence of infectious complications | 4, 12 weeks and 1years after surgery | Infectious complications include, but are not limited to, pneumonia, surgical site infection, etc. |
| Incidence of unplanned hospital readmission within 4 and 12 weeks after surgery | 4 and 12 weeks after surgery | Unplanned hospital readmission |
| Length of hospital stay | Through patients discharge, an average of 7 days after surgery | Length of hospital stay |
| Hospitalization costs | Through patients discharge, an average of 7 days after surgery | Hospitalization costs |
| Quality of life scores | at 4, 12 weeks and 1 years after surgery | Quality of life was assessed using the EuroQol Five-Dimensional Questionnaire (EQ-5D) EuroQol Five-Dimensional Questionnaire (EQ-5D): The EQ-5D includes a visual analog scale (EQ-VAS) ranging from 0 to 100, where higher scores indicate better health status. |
Countries
China
Contacts
CONTACTMin Yan, Doctor
Outcome results
None listed